Page 26 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Progress in the research of pathology and therapy in liver fibrosis

derivative suppressed hepatic stellate cell activation and 2022;298:115599.
ameliorated liver fibrosis by blocking TGF-β1 signalling. doi: 10.1016/j.jep.2022.115599
Liver Int. 2023;43:718-73.
125. Li XM, Peng JH, Sun ZL, et al. Chinese medicine CGA
doi: 10.1111/liv.15488
formula ameliorates DMN-induced liver fibrosis in rats via
116. Zhao XM, Zhang J, Liang YN, Niu YC. Astragaloside inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling
IV synergizes with ferulic acid to alleviate hepatic pathways. Acta Pharmacol Sin. 2016;37(6):783-793.
fibrosis in bile duct-ligated cirrhotic rats. Dig Dis Sci.
2020;65(10):2925-2936. doi: 10.1038/aps.2016.35
126. Tian H, Liu L, Li Z, et al. Chinese medicine CGA formula
doi: 10.1007/s10620-019-06017-3
ameliorates liver fibrosis induced by carbon tetrachloride
117. Sun X, Huang X, Zhu X, et al. HBOA ameliorates CCl4- involving inhibition of hepatic apoptosis in rats.
incuded liver fibrosis through inhibiting TGF-β1/Smads, J Ethnopharmacol. 2019;232:227-235.
NF-κB and ERK signaling pathways. Biomed Pharmacother.
2019;115:108901. doi: 10.1016/j.jep.2018.11.027
doi: 10.1016/j.biopha.2019.108901 127. Wang Y, Li Y, Zhang H, et al. Pharmacokinetics-based
comprehensive strategy to identify multiple effective
118. Wu L, Zhang Q, Mo W, et al. Quercetin prevents hepatic components in Huangqi decoction against liver fibrosis.
fibrosis by inhibiting hepatic stellate cell activation and Phytomedicine. 2021;84:153513.
reducing autophagy via the TGF-β1/Smads and PI3K/Akt
pathways. Sci Rep. 2017;7(1):9289. doi: 10.1016/j.phymed.2021.153513
doi: 10.1038/s41598-017-09673-5 128. Cheng Y, Liu P, Hou TL, Maimaitisidike M, Ababaikeli R,
Abudureyimu A. Mechanisms of Huangqi decoction
119. Liu N, Feng J, Lu X, et al. Isorhamnetin inhibits liver fibrosis granules () on hepatitis B cirrhosis patients based on RNA-
by reducing autophagy and inhibiting extracellular matrix sequencing. Chin J Integr Med. 2019;25(7):507-514.
formation via the TGF-β1/Smad3 and TGF-β1/p38 MAPK
pathways. Mediators Inflamm. 2019;2019:6175091. doi: 10.1007/s11655-018-3013-3
doi: 10.1155/2019/6175091 129. Zhou Y, Wu R, Cai FF, et al. Xiaoyaosan decoction
alleviated rat liver fibrosis via the TGFβ/Smad and Akt/
120. Yu B, Qin SY, Hu BL, Qin QY, Jiang HX, Luo W. FoxO3 signaling pathways based on network pharmacology
Resveratrol improves CCL4-induced liver fibrosis in analysis. J Ethnopharmacol. 2021;264:113021.
mouse by upregulating endogenous IL-10 to reprogramme
macrophages phenotype from M(LPS) to M(IL-4). Biomed doi: 10.1016/j.jep.2020.113021
Pharmacother. 2019;117:109110. 130. Lu Y, Li M, Zhou Q, et al. Dynamic network biomarker
doi: 10.1016/j.biopha.2019.109110 analysis and system pharmacology methods to explore the
therapeutic effects and targets of Xiaoyaosan against liver
121. Zhu L, Mou Q, Wang Y, Zhu Z, Cheng M. Resveratrol contributes cirrhosis. J Ethnopharmacol. 2022;294:115324.
to the inhibition of liver fibrosis by inducing autophagy via the
microRNA20amediated activation of the PTEN/PI3K/AKT doi: 10.1016/j.jep.2022.115324
signaling pathway. Int J Mol Med. 2020;46(6):2035-2046. 131. Liang B, Gao L, Wang F, et al. The mechanism research
doi: 10.3892/ijmm.2020.4748 on the anti-liver fibrosis of emodin based on network
pharmacology. IUBMB Life. 2021;73(9):1166-1179.
122. Rong G, Chen Y, Yu Z, et al. Synergistic effect of Biejia-
Ruangan on fibrosis regression in patients with chronic doi: 10.1002/iub.2523
hepatitis B treated with entecavir: A multicenter, 132. Tang YX, Liu M, Liu L, et al. Lipophilic constituents in salvia
randomized, double-blind, placebo-controlled trial. J Infect miltiorrhiza inhibit activation of the hepatic stellate cells by
Dis. 2022;225(6):1091-1099. suppressing the JAK1/STAT3 signaling pathway: A network
doi: 10.1093/infdis/jiaa266 pharmacology study and experimental validation. Front
Pharmacol. 2022;13:770344.
123. Cheng DY, Zhao ZM, Wan G, et al. Impact of Fuzheng Huayu
tablet on antiviral effect of entecavir in patients with hepatitis B doi: 10.3389/fphar.2022.770344
cirrhosis. Hepatobiliary Pancreat Dis Int. 2022;21(5):479-484.
133. Xiao HM, Shi MJ, Jiang JM, et al. Efficacy and safety of
doi: 10.1016/j.hbpd.2022.03.007 AnluoHuaxian pills on chronic hepatitis B with normal or
minimally elevated alanine transaminase and early liver
124. Zhao ZM, Zhu CW, Huang JQ, et al. Efficacy and safety of fibrosis: A randomized controlled trial. J Ethnopharmacol.
Fuzheng Huayu tablet on persistent advanced liver fibrosis
following 2 years entecavir treatment: A single arm clinical 2022;293:115210.
objective performance criteria trial. J Ethnopharmacol. doi: 10.1016/j.jep.2022.115210

Volume 9 Issue 3 (2025) 18 doi: 10.36922/ejmo.8125